(-0.05%) 5 475.50 points
(-0.11%) 38 777 points
(-0.01%) 19 919 points
(0.15%) $80.45
(1.29%) $2.82
(0.21%) $2 333.80
(-0.24%) $29.32
(-0.23%) $968.70
(0.01%) $0.932
(-0.18%) $10.63
(0.05%) $0.788
(-1.87%) $86.80
Live Chart Being Loaded With Signals
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells...
Stats | |
---|---|
Šios dienos apimtis | 5.67M |
Vidutinė apimtis | 5.71M |
Rinkos kapitalizacija | 2.26B |
EPS | $-0.420 ( Q1 | 2024-05-09 ) |
Kita pelno data | ( $0 ) 2024-08-06 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-4.46 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0130 (0.16%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-11 | Countouriotis Athena | Buy | 49 303 | Deferred Restricted Stock Unit |
2024-06-11 | Yarno Wendy L | Buy | 49 303 | Deferred Restricted Stock Unit |
2024-06-11 | Weiser Michael | Buy | 49 303 | Deferred Restricted Stock Unit |
2024-06-11 | Maynard Ryan D | Buy | 49 303 | Deferred Restricted Stock Unit |
2024-06-11 | Dukes Iain D. | Buy | 98 607 | Deferred Restricted Stock Unit |
INSIDER POWER |
---|
95.32 |
Last 99 transactions |
Buy: 13 500 253 | Sell: 312 775 |
Tūris Koreliacija
Iovance Biotherapeutics Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
LRMR | 0.904 |
EQ | 0.9 |
CFLT | 0.898 |
TARA | 0.883 |
NTWK | 0.864 |
FROG | 0.86 |
TRMB | 0.86 |
CLBT | 0.855 |
PXLW | 0.853 |
ALRM | 0.852 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
BLKB | -0.908 |
SSRM | -0.874 |
CAR | -0.842 |
FINW | -0.842 |
DSWL | -0.827 |
CYAN | -0.825 |
EGAN | -0.823 |
BIOL | -0.821 |
SGLY | -0.817 |
WTER | -0.812 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Iovance Biotherapeutics Koreliacija - Valiuta/Žaliavos
Iovance Biotherapeutics Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $1.19M |
Bruto pelnas: | $-31.94M (-2 686.12 %) |
EPS: | $-1.890 |
FY | 2023 |
Pajamos: | $1.19M |
Bruto pelnas: | $-31.94M (-2 686.12 %) |
EPS: | $-1.890 |
FY | 2022 |
Pajamos: | $0 |
Bruto pelnas: | $-21.14M (0.00 %) |
EPS: | $-2.45 |
FY | 2021 |
Pajamos: | $0.00 |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-2.20 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Iovance Biotherapeutics
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.